| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Ixekizumab |
| Brand | Taltz® |
| Indication | For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 28/06/2016 |
| Rapid review completed | 26/07/2016 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended at the submitted price |
September 2016
The HSE has approved reimbursement following confidential price negotiations.